Thyroiditis comprises a heterogeneous group of inflammatory disorders of the thyroid gland that share disruption of follicular integrity and immune-endocrine regulation but differ profoundly in etiology, kinetics of injury, clinical presentation, and functional consequences. From a pathophysiological perspective, inflammation may cause passive release of preformed hormones with transient thyrotoxicosis, reduced biosynthetic capacity with hypothyroidism, or alternating hyperfunctional and hypofunctional phases reflecting the dynamic balance among follicular destruction, tissue repair, and immune remodeling. In clinical practice, determining whether thyroid dysfunction is driven by hormone overproduction or by hormone leakage from destructive thyroiditis is crucial because it directs the differential diagnosis and therapeutic strategy.
From a nosological perspective, the most useful classification integrates the pathogenetic mechanism, including autoimmune, post-viral, bacterial suppurative, iatrogenic, and fibroinflammatory forms, with the temporal course, including acute, subacute, and chronic forms. It also recognizes that some entities lie along a continuum and may share biomarkers and ultrasonographic phenotypes. This page provides an integrated overview of the main forms of thyroiditis, emphasizing the molecular and immunological mechanisms responsible for follicular injury, the reasons for clinical variability, and the key elements required to establish a coherent diagnostic and therapeutic pathway.
The epidemiology of thyroiditis is strongly influenced by the fact that the term encompasses several distinct clinical entities with different incidences and determinants. Autoimmune forms, particularly chronic lymphocytic thyroiditis, including Hashimoto thyroiditis and related variants, are the most frequent cause of non-nodular thyroid dysfunction in iodine-sufficient regions. They show a marked female predominance and are associated with genetic susceptibility and other organ-specific autoimmune disorders. At the opposite end of the spectrum, acute suppurative thyroiditis is rare but clinically critical because of its potential progression to abscess formation, sepsis, and compressive complications. Its distribution is influenced by predisposing anatomical factors, particularly abnormalities such as a pyriform sinus fistula, and by immunosuppressive conditions.
Subacute thyroiditis, also known as De Quervain or granulomatous thyroiditis, often follows a seasonal or post-infectious pattern and typically affects middle-aged adults. Its incidence varies according to the diagnostic criteria applied and clinicians’ ability to recognize mildly painful forms or atypical presentations. In this setting, risk is related less to structural predisposing factors than to the likelihood of an infectious trigger and the host immune response, which may determine the extent of follicular injury and the variable duration of the subsequent hypothyroid phase.
A rapidly evolving epidemiological area concerns iatrogenic and medication-induced thyroiditis. The expansion of immunotherapy in oncology has increased the frequency of immune-mediated thyroid dysfunction, often presenting as destructive thyroiditis followed by persistent hypothyroidism. Cardiovascular treatments such as amiodarone also interact with thyroid physiology through iodine loading, interference with peripheral deiodination, and, in certain patient subgroups, induction of thyrotoxicosis through distinct mechanisms. In all these scenarios, the observed incidence reflects not only disease biology but also monitoring frequency, follow-up intensity, and attention to the early recognition of nonspecific symptoms.
Regarding risk factors, autoimmune forms are associated with family history, a permissive genetic background, and environmental variables that modulate thyroid-specific immune tolerance. Autoantibody positivity, including anti-thyroid peroxidase and anti-thyroglobulin antibodies, identifies a predisposing immunological background that may remain subclinical for years and become clinically apparent during phases of immune modulation, such as the postpartum period or exposure to immunotherapy. Postpartum thyroiditis occurs in the setting of immune rebound after pregnancy, when the restoration of cellular immune reactivity promotes the emergence of latent thyroid autoimmunity.
Predisposing factors for suppurative infectious forms include abnormalities of embryological migration and incomplete closure of branchial structures, which facilitate bacterial inoculation into the thyroid parenchyma. In adults, hematogenous spread from oropharyngeal or respiratory foci and conditions that impair immune barriers may also contribute. Rare fibroinflammatory forms, such as Riedel thyroiditis and immunoglobulin G4-related variants, do not have a conventional large-scale epidemiological profile but require a high index of clinical suspicion when a hard, infiltrative, compressive goiter is observed in association with systemic features compatible with multisystem fibroinflammatory disease.
The etiology of thyroiditis can be organized into broad pathogenetic categories that, although simplified, help predict the clinical course and laboratory profile. In autoimmune thyroiditis, follicular injury results from loss of tolerance toward thyroid-specific antigens, particularly thyroid peroxidase and thyroglobulin, and from activation of cellular and humoral responses that progressively remodel the architecture of the gland. Autoreactive T cells and cytotoxic mechanisms, together with autoantibody production, promote lymphocytic infiltration, formation of intrathyroidal germinal centers, thyrocyte apoptosis, and progressive fibrosis. In this setting, the pathophysiological course typically progresses toward chronic hypothyroidism, although initial episodes of hashitoxicosis may occur because of the release of preformed hormones during periods of more intense follicular injury.
Postpartum thyroiditis and silent, or painless, thyroiditis are often considered variants of destructive lymphocytic thyroiditis occurring on an autoimmune background. Their common denominator is a phase of thyrotoxicosis caused not by overproduction but by loss of follicular containment, followed by a hypothyroid phase of variable duration. The central pathophysiological feature is the dissociation between the quantity of hormone released and the ability to synthesize new hormone. When follicles are damaged, hormone stored in the colloid enters the circulation, while the capacity to organify iodine and replenish hormone stores decreases. This produces a biphasic course that resolves in most cases but may result in permanent hypothyroidism when the injury exceeds the threshold of functional compensation or when established chronic autoimmunity coexists.
In subacute granulomatous thyroiditis, or De Quervain thyroiditis, the etiology is classically post-infectious, and the pathogenetic mechanism is dominated by intensely painful inflammation with follicular destruction and a granulomatous response. Macrophages and multinucleated giant cells participate in the clearance of colloid material released from damaged follicles. Pain and elevation of inflammatory markers reflect the intensity of the local inflammatory response. From a pathophysiological perspective, the most typical pattern consists of an initial phase of release-related thyrotoxicosis, a transient euthyroid phase, a hypothyroid phase caused by depletion of stored hormone, and eventual functional recovery through follicular reconstruction. The duration of each phase depends on the extent of the initial injury and the tissue repair capacity, with substantial interindividual variability.
Suppurative infectious thyroiditis has a bacterial or, less commonly, fungal etiology and represents a completely different pathogenetic model. The thyroid is relatively resistant to infection because of its rich vascular supply, lymphatic drainage, high iodine content, and fibrous capsule. When infection develops, a facilitating factor is usually present, such as an anatomical abnormality, direct inoculation, or hematogenous dissemination. The inflammation is neutrophilic, may progress to an abscess, and causes pain, fever, and sometimes compressive manifestations or airway compromise. In these cases, thyroid dysfunction is not the central issue. The primary priorities are controlling the infection, preventing dissemination, and managing any purulent collection.
Iatrogenic and medication-associated thyroiditis involves multiple mechanisms. With immune checkpoint inhibitors, the pivotal event is immune activation that disrupts tolerance and promotes intrathyroidal infiltration with follicular injury, often producing destructive thyroiditis followed by rapid progression to hypothyroidism. Amiodarone causes at least three levels of interference: a massive iodine load that alters intrathyroidal homeostasis, modulation of peripheral conversion of T4 to T3 through deiodinase inhibition, and the possibility of thyrotoxicosis caused by iodine-induced hyperfunction in a predisposed thyroid or by destructive thyroiditis with release of preformed hormones. Mixed forms are pathophysiologically plausible because amiodarone acts on both the thyroid substrate and peripheral hormone regulation.
Rare fibroinflammatory forms, such as Riedel thyroiditis and immunoglobulin G4-related thyroiditis, are characterized by replacement of the parenchyma with dense fibrous tissue and chronic inflammation that may extend beyond the thyroid capsule. This produces an infiltrative pattern with compression of the trachea, esophagus, and neural structures. In this setting, the pathophysiology is dominated by the mass effect and progressive fibrosis rather than by the biphasic functional instability typical of destructive thyroiditis. Nevertheless, loss of thyroid reserve may lead to hypothyroidism, and the differential diagnosis with infiltrative neoplasms requires rigorous evaluation.
A useful overarching principle is to distinguish thyrotoxicosis caused by overproduction from thyrotoxicosis caused by destruction. In destructive thyroiditis, increased free thyroxine and free triiodothyronine levels result from the release of preformed hormone and are generally self-limited. Radioiodine uptake is typically low, and clinical response is better with beta-blockade and control of inflammation than with antithyroid agents. By contrast, when thyrotoxicosis is caused by overproduction, as in some iodine-induced forms or concomitant Graves disease, the biosynthetic pathway is active and treatment must target thyroid hormone synthesis. This pathophysiological distinction is the central principle that ensures consistency throughout the diagnostic and therapeutic management of thyroiditis.
The clinical presentation of thyroiditis depends on the intensity of local inflammation, possible capsular involvement, and, above all, the functional phase of the gland. A major initial distinction in the medical history is the presence of anterior neck pain and tenderness on palpation, which suggest subacute granulomatous thyroiditis or suppurative thyroiditis. Their absence is more consistent with silent thyroiditis, postpartum thyroiditis, or chronic autoimmune thyroiditis in a hypofunctional phase. Pain in subacute thyroiditis may radiate to the jaw and ear and is often associated with low-grade fever or fever, myalgia, and marked fatigue, reflecting systemic inflammatory activation.
Manifestations of thyrotoxicosis during the initial destructive phase include palpitations, tremor, heat intolerance, sweating, weight loss, and anxiety. However, in many forms of thyroiditis, symptom intensity may be moderate and disproportionate to hormone levels, partly because the thyrotoxic phase may be brief. In frail patients or those with cardiac disease, even transient thyrotoxicosis may precipitate heart failure, ischemia, or arrhythmias. Its clinical relevance therefore depends not only on duration but also on the underlying cardiovascular condition.
During the hypothyroid phase, typical symptoms include fatigue, weight gain, cold intolerance, constipation, dry skin, and psychomotor slowing. In destructive thyroiditis, this phase may emerge when colloid stores have been depleted and hormone synthesis is temporarily inadequate. Its duration varies. In some conditions, such as postpartum or silent thyroiditis, thyroid function may recover, whereas in chronic autoimmune forms the deficiency tends to become permanent.
On physical examination, subacute thyroiditis commonly presents with an enlarged and tender thyroid. Suppurative thyroiditis may produce more marked local findings, sometimes including fluctuation when a collection is present, together with systemic signs of infection. In chronic autoimmune thyroiditis, the gland may be enlarged and irregular because of lymphocytic goiter or, in advanced stages, small and fibrotic. Infiltrative fibroinflammatory thyroiditis presents with a hard, woody, poorly mobile gland, sometimes associated with dysphagia, dysphonia, or dyspnea caused by compression. This presentation requires a diagnostic approach primarily aimed at excluding infiltrative thyroid malignancies.
A clinically important consideration is the possibility of mixed presentations. A postpartum patient with fatigue, anxiety, and palpitations may be considered to have normal puerperal changes or a mood disorder, while postpartum thyroiditis in its thyrotoxic phase may be the primary cause of the symptoms. Similarly, a patient receiving immunotherapy who develops fatigue and weight loss may have multiple concurrent endocrine disorders, with immune-mediated thyroiditis representing only one component. Assessment of the temporal sequence of symptoms and correlation with treatments, pregnancy, recent infections, and local pain remain essential first-line clinical tools.
Thyroiditis should be suspected when thyroid dysfunction is accompanied by clinical or contextual features compatible with an inflammatory thyroid process rather than autonomous hyperfunction or nodular disease. Thyrotoxicosis with suppressed thyroid-stimulating hormone and adrenergic symptoms should prompt assessment of whether the condition is caused by hormone overproduction, as in Graves disease, or by destructive release. The presence of neck pain, increased inflammatory markers, and a recent history of upper respiratory tract infection suggests subacute thyroiditis. By contrast, painless thyrotoxicosis, particularly during the postpartum period or immunotherapy, is highly suggestive of silent or immune-mediated destructive thyroiditis.
Suspicion should also be high when hypothyroidism develops in individuals with positive thyroid autoantibodies or a family history of autoimmune disease, as this may represent the clinical emergence of chronic lymphocytic thyroiditis. In these cases, a detailed medical history should assess the gradual onset of symptoms, obstetric history, the possible association with other autoimmune disorders, and exposure to medications that affect thyroid function. In patients who have received cervical radiotherapy or are being treated with endocrine-modulating therapies, the threshold for suspicion should be even lower.
Another critical scenario is suspected suppurative thyroiditis. Severe pain, high fever, leukocytosis, and marked local signs should prompt consideration of thyroid infection despite its rarity, particularly in children or in patients with recurrent episodes, which suggest a predisposing anatomical abnormality. Rapid progression and the risk of complications require prompt diagnostic evaluation and, when necessary, coordinated management with surgical and infectious disease specialists.
Finally, infiltrative fibroinflammatory thyroiditis should be suspected when a hard, compressive thyroid mass progresses rapidly or shows features of local invasiveness. In such cases, the issue is not merely whether thyroiditis is present, but rather a complex differential diagnosis in which Riedel thyroiditis and immunoglobulin G4-related forms are rare but genuine alternatives to infiltrative malignancies. They must be distinguished through imaging, cytological or histological examination, and systemic assessment. As a practical rule, compression and infiltration require an approach that prioritizes airway safety and histological characterization of the process.
The diagnosis of thyroiditis is based on integrated clinical, laboratory, and instrumental assessment, with three primary objectives: distinguishing destructive forms from hyperproductive forms, identifying infectious forms requiring urgent treatment, and recognizing conditions in which cytological or histological confirmation is necessary. Initial testing includes a complete thyroid profile with thyroid-stimulating hormone, free thyroxine, and, when appropriate, free triiodothyronine. During destructive thyrotoxicosis, free thyroxine is often relatively more elevated than free triiodothyronine, consistent with release from colloid and changes in peripheral conversion. In hyperfunction caused by active synthesis, free triiodothyronine may be relatively higher because of increased production and conversion.
Inflammatory markers, particularly the erythrocyte sedimentation rate and C-reactive protein, are especially useful in painful subacute thyroiditis, in which they are often elevated and correlate with inflammatory activity. They may remain normal in chronic autoimmune thyroiditis, whereas suppurative thyroiditis may be associated with leukocytosis and a marked infectious profile. Measurement of thyroid autoantibodies, including anti-thyroid peroxidase and anti-thyroglobulin antibodies, supports the diagnosis of autoimmune thyroiditis and identifies a predisposing background in silent and postpartum forms. Measurement of thyroid-stimulating hormone receptor antibodies is useful when the differential diagnosis includes Graves disease, particularly in patients with painless thyrotoxicosis, because the therapeutic implications are substantial.
Thyroid ultrasonography is the principal first-line imaging modality. Autoimmune thyroiditis typically produces a heterogeneous, hypoechoic echotexture with variable vascularity. Subacute thyroiditis may present with focal or multifocal, poorly defined hypoechoic areas that reflect inflammation and destruction. In suppurative thyroiditis, ultrasonography may identify a collection compatible with an abscess and guide drainage procedures. Doppler assessment may help distinguish overproduction from destruction. Vascularity may not be markedly increased in destructive forms, whereas hyperemia may be more prominent in autoimmune hyperfunction, although this is not an absolute criterion.
In selected cases, radioiodine uptake or equivalent functional imaging methods provide decisive information. Low uptake supports thyrotoxicosis caused by destructive thyroiditis, whereas normal or increased uptake suggests hormone overproduction. This assessment is particularly useful when the clinical picture is subtle or when coexisting antibodies complicate interpretation. In patients receiving amiodarone, uptake interpretation may be difficult because of iodine excess, and the diagnostic process must integrate clinical context, imaging, antibody status, and the biochemical pattern.
When the presentation suggests infiltrative or fibroinflammatory thyroiditis, fine-needle aspiration may be nondiagnostic or poorly representative because of extensive fibrosis. In such cases, the decision to pursue additional biopsy procedures, advanced imaging, or multidisciplinary assessment depends on clinical risk and the need to exclude anaplastic thyroid carcinoma or thyroid lymphoma. In suppurative thyroiditis, identification of the pathogen through cultures of aspirated material, when obtainable, guides targeted antimicrobial therapy and may help link the episode to a primary infectious focus or predisposing condition.
A functional classification of thyroiditis based on pathogenetic mechanisms is often more useful than classification based solely on temporal course. Broad categories include autoimmune thyroiditis, including chronic lymphocytic forms and variants, subacute post-infectious thyroiditis, including painful granulomatous forms, suppurative infectious thyroiditis, iatrogenic thyroiditis, including immune-mediated and medication-associated follicular injury, and infiltrative fibroinflammatory thyroiditis, including Riedel thyroiditis and immunoglobulin G4-related forms. This taxonomy helps predict the dominant clinical profile: biphasic functional instability in destructive forms, progressive hypothyroidism in chronic autoimmune forms, an infectious emergency in suppurative forms, and compressive risk with an oncological differential diagnosis in fibrotic infiltrative forms.
A second classification axis concerns the functional course over time: isolated thyrotoxicosis, typical of the initial destructive phase, a biphasic course with thyrotoxicosis followed by hypothyroidism, isolated hypothyroidism, more common in chronic autoimmune disease or late stages after extensive injury, and a relapsing course, which may occur in subacute thyroiditis, some silent forms, and autoimmune settings. In clinical practice, this axis is important because it determines monitoring intensity and the likelihood that stable replacement therapy will be required.
Severity can be assessed across three dimensions. Systemic severity depends on the intensity of thyrotoxicosis and cardiovascular risk, even when the phase is transient. Local severity depends on pain, compressive manifestations, and the risk of compromise of the airway or neural structures. Prognostic severity depends on the likelihood of permanent hypothyroidism and the presence of underlying conditions that stabilize autoimmunity or promote recurrence. This three-dimensional approach prevents severity from being reduced to the free thyroxine level alone and allows follow-up to be tailored to the patient’s actual risk.
Treatment of thyroiditis must be mechanism-guided. During destructive thyrotoxic phases, the primary objective is control of adrenergic symptoms and inflammation rather than suppression of hormone synthesis. In clinical practice, beta-blockers are frequently used for palpitations and tremor, with the specific agent and dosage selected according to the patient’s cardiovascular profile. Antithyroid agents are generally ineffective in destructive thyroiditis because there is no sustained hormone overproduction to inhibit. Their use without a valid indication exposes patients to adverse effects without providing benefit.
In painful subacute thyroiditis, treatment of pain and inflammation is central. Nonsteroidal anti-inflammatory agents may be sufficient in mild forms, whereas more severe or refractory disease may require glucocorticoids followed by gradual dose reduction. The objective is to suppress inflammation and shorten the painful phase while carefully balancing benefits and risks. The pathophysiological rationale is that granulomatous inflammation drives both pain and active follicular injury. Reducing inflammation accelerates clinical resolution and improves quality of life, although thyroid function must continue to be monitored during subsequent phases.
In chronic autoimmune thyroiditis, treatment is not anti-inflammatory but consists of hormone replacement when clinically relevant hypothyroidism develops. Levothyroxine is the cornerstone of treatment for hypothyroidism caused by chronic thyroiditis, with individualized titration according to age, cardiovascular comorbidities, and clinical objectives. In subclinical forms, the decision to treat requires consideration of symptoms, the degree of thyroid-stimulating hormone elevation, antibody status, pregnancy plans, and the risk of progression. The underlying principle is that thyroiditis may reduce functional reserve and destabilize hormonal balance, particularly during periods of increased demand such as pregnancy.
Postpartum and silent thyroiditis require a pragmatic approach. During the thyrotoxic phase, treatment is predominantly symptomatic and based on beta-blockers. During the hypothyroid phase, the need for levothyroxine is assessed according to symptoms, the degree of hypothyroidism, and the reproductive context. Some patients recover and may undergo a supervised trial of treatment withdrawal after an appropriate period, whereas others develop permanent hypothyroidism, particularly when the autoimmune background is pronounced.
In acute suppurative thyroiditis, treatment is time-dependent and includes antimicrobial therapy appropriate to the suspected pathogen and clinical severity, management of complications, and drainage when a collection is present. Identifying and correcting predisposing conditions, such as anatomical abnormalities in recurrent cases, is an integral part of treatment because it reduces the risk of recurrence. Management of thyroid dysfunction, when present, is secondary to infection control.
Iatrogenic thyroiditis requires specific strategies. In immunotherapy-associated immune-mediated dysfunction, the condition often progresses to hypothyroidism, and management is primarily based on hormone replacement, with close monitoring because the transition from the thyrotoxic to the hypothyroid phase may be rapid. In amiodarone-associated presentations, determination of the underlying mechanism is essential. When a destructive mechanism predominates, symptom control and suppression of inflammation are the priorities. When iodine-induced overproduction in a predisposed thyroid predominates, management is directed toward reducing hormone synthesis and addressing the underlying thyroid substrate. Clinical complexity arises because thyrotoxicosis in patients with cardiac disease may carry substantial risk and require multidisciplinary decision-making.
Follow-up in thyroiditis should be tailored to the expected pathophysiological course and the specific risks associated with the suspected form. In destructive thyroiditis, the priority is to identify functional transition. A phase of marked hypothyroidism may follow thyrotoxicosis, and its timing is not fixed. Monitoring thyroid function with thyroid-stimulating hormone and free thyroxine at intervals appropriate to the clinical picture is therefore essential to prevent both undertreatment of symptomatic hypothyroidism and overtreatment with levothyroxine in patients who are likely to recover spontaneously. Follow-up should be more intensive in patients with cardiac comorbidities because even temporary fluctuations in thyroid hormone levels may have clinically significant consequences.
In chronic autoimmune thyroiditis, follow-up is directed toward the stability of replacement therapy and progression of thyroid dysfunction. Adjustment of levothyroxine is guided by clinical and biochemical targets and must account for variables that alter absorption and requirements, including changes in body weight, pregnancy, interfering medications, and gastrointestinal disorders. In individuals with thyroid autoantibodies but preserved thyroid function, surveillance aims to detect loss of thyroid reserve and identify progression to clinical hypothyroidism at an early stage, particularly in settings of increased metabolic demand.
In subacute thyroiditis, effective follow-up includes assessment of the resolution of pain and inflammatory markers and, more importantly, surveillance for the subsequent hypothyroid phase, which may require temporary treatment or, in a minority of patients, progress to persistent hypothyroidism. Monitoring also allows recognition of relapses, which have therapeutic implications because they may require renewed control of inflammation and reassessment of the risks associated with repeated treatment courses.
In immunotherapy-related thyroiditis, follow-up is often defined by oncology protocols but must also be targeted from an endocrinological perspective. Hypothyroidism may develop rapidly, and its manifestations may overlap with cancer-related fatigue. Scheduled monitoring of thyroid hormones is therefore an integral component of treatment safety. Surveillance is also mandatory in amiodarone-associated thyroiditis because of the long half-life of the medication and the possibility of delayed progression of thyroid dysfunction, requiring the clinical strategy to be adapted to the patient’s cardiac profile.
In suppurative thyroiditis and infiltrative fibrotic forms, follow-up includes confirmation of local resolution, prevention of compressive complications, and verification of stable thyroid function. After suppurative thyroiditis, predisposing factors should be investigated, particularly in recurrent cases, because correction of an anatomical abnormality reduces the risk of further infections. In fibrosing forms, clinical and instrumental surveillance focuses on compressive progression and the possible need for specific interventions, with continued attention to respiratory safety and definitive characterization of the underlying process.
The prognosis of thyroiditis is generally favorable when the specific form is correctly identified and management is consistent with its pathophysiology. In subacute and silent destructive thyroiditis, functional prognosis depends on the amount of thyroid parenchyma that recovers after the inflammatory phase. Many patients return to euthyroidism, but some develop permanent hypothyroidism, particularly when pre-existing autoimmunity is present or the initial injury was extensive. Postpartum thyroiditis has a variable clinical prognosis. It may resolve, but it increases the risk of recurrence in subsequent pregnancies and progression to chronic autoimmune thyroiditis, making targeted surveillance essential during future reproductive periods.
The most relevant complications depend on the functional phase and the patient’s underlying condition. Transient thyrotoxicosis may precipitate cardiovascular complications in predisposed individuals, including rhythm instability and worsening of pre-existing heart disease. Untreated hypothyroidism may cause metabolic deterioration, dyslipidemia, and reduced functional performance, with a substantial impact on quality of life. In practical terms, a common but clinically silent complication is the incorrect attribution of symptoms to non-endocrine causes, which delays diagnosis and treatment, particularly when pain is absent and the presentation consists of nonspecific fatigue.
In subacute thyroiditis, a clinically important complication is recurrence of pain and inflammation, which may require retreatment and prolong functional instability. Complications of suppurative thyroiditis include abscess formation, extension of infection into the tissues of the neck, sepsis, and, in compressive cases, airway compromise. Prognosis in these cases depends on the prompt initiation of antimicrobial treatment and drainage when required, as well as identification of anatomical abnormalities that predispose to recurrence.
Infiltrative fibroinflammatory forms may be complicated by tracheal and esophageal compression and involvement of the laryngeal nerves, resulting in dyspnea, dysphagia, and dysphonia. The differential diagnosis with infiltrative malignancy also represents a clinical risk because management must avoid delays in treating aggressive disease while limiting unnecessary interventions in rare inflammatory disorders. In immunotherapy-associated iatrogenic thyroiditis, the most common and persistent complication is permanent hypothyroidism requiring stable replacement therapy. Overall prognosis depends on the oncological course, but prompt correction of thyroid dysfunction reduces symptoms and supports continuity of cancer treatment.
In summary, the prognosis of thyroiditis is determined not only by the magnitude of hormonal abnormalities but also by accurate identification of the causal mechanism, appropriate management of the different functional phases, and prevention of complications specific to each form. An approach centered on pathogenesis and clinical course reduces therapeutic errors, limits unnecessary exposure to nonindicated treatments, and protects patients at increased cardiovascular or infectious risk.